文献速递免疫规划

巴西里约热内卢HIV感染儿童和青少年两剂C群脑膜炎球菌结合疫苗免疫后的安全性和免疫应答

Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
PubMed 文献 · Vaccine · 2017-10-31

在巴西里约热内卢一家HIV关怀参考中心,对2-18岁CD4≥15%的HIV感染儿童和青少年接种两剂C群脑膜炎球菌结合疫苗(间隔12-18个月),加强剂后78.8%达到血清保护,几何平均滴度较基础免疫显著升高(p<0.01),38%出现轻微不良事件,结论认为加强剂安全且免疫原性高。

要点

  • 加强剂后78.8%(108/137)受试者达到血清保护,几何平均滴度较基础免疫显著升高(p<0.01)。
  • 38%受试者在第二剂后出现轻微不良事件。
  • 入组时病毒载量检测不到(OR=7.1,95%CI:2.14-23.37)与加强免疫后血清保护相关。

核心结论

  • C群脑膜炎球菌结合疫苗加强剂安全,且在基础免疫后12-18个月仍诱导高血清保护率;作者认为应在达到最大病毒学抑制后接种,结果支持在免疫功能恢复的HIV感染儿童和青少年中采用两剂C群脑膜炎球菌结合疫苗进行基础免疫。

研究设计与样本

  • 在巴西里约热内卢一家HIV关怀参考中心开展的免疫原性与不良事件评估研究,纳入2-18岁CD4+ T淋巴细胞≥15%、无活动性感染或抗生素使用的HIV感染者,接种2剂C群脑膜炎球菌寡糖-CRM197结合疫苗,间隔12-18个月。

主要发现

  • 共入组156例,137例接受了加强剂C群脑膜炎球菌结合疫苗;55%为女性,中位年龄12岁。
  • 78.8%(108/137)受试者达到血清保护,几何平均滴度较基础免疫剂量后显著更高(p<0.01)。
  • 第二剂C群脑膜炎球菌结合疫苗后38%出现轻微不良事件。
  • 逻辑回归中,入组时病毒载量检测不到(OR=7.1,95%CI:2.14-23.37)和加强免疫访视时可能较高的CD4百分比(OR=1.1,95%CI:1.01-1.17)与加强剂后血清保护相关。

关键数值与推荐

  • 血清保护定义为人血清杀菌活性(hSBA)滴度≥1:4。
  • 不良事件在每次接种后20分钟、3天和7天评估。

临床怎么用

  • 作者认为C群脑膜炎球菌结合疫苗应在达到最大病毒学抑制后接种。
  • 作者结论支持在免疫功能恢复的HIV感染儿童和青少年中采用两剂C群脑膜炎球菌结合疫苗进行基础免疫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We aimed to evaluate immunogenicity and adverse events (AEs) after a booster dose of Meningococcal C conjugated (MCC) vaccine in HIV-infected children and adolescents, who had a previous low seroconversion rate after priming with MCC, at a reference HIV-care center in Rio de Janeiro. METHODS: 2-18 years old HIV-infected subjects with CD4+ T-lymphocyte cell (CD4) ≥15%, without active infection or antibiotic use, were enrolled to receive 2 doses of conjugated meningococcal C oligosaccharide-CRM197 12-18 months apart. All patients were evaluated before and 1-2 months after immunization for seroprotection [defined as human serum bactericidal activity (hSBA) titer ≥1:4]. AEs were assessed at 20 min, 3 and 7 days after each dose. Factors independently associated with seroprotection were studied. RESULTS: 156 subjects were enrolled and 137 received a booster MCC dose. 55% were female, and median age was 12 years. Eight-nine percent were receiving combined antiretroviral therapy (cART) at the booster visit (median duration of 7.7 years), 59.9% had undetectable viral load (VL) at baseline, and 56.2% at the booster visit. Seroprotection was achieved in 78.8% (108/137) subjects, with a significantly higher GMT than after the priming dose (p < 0.01). Mild AEs were experienced after a second MCC dose (38%). In logistic regression, undetectable viral load at entry [odds ratio (OR) = 7.1, 95% confidence interval (95%CI): 2.14-23.37], and probably higher CD4 percent at the booster immunization visit (OR): 1.1, 95%CI: 1.01-1.17 were associated with seroprotection after a booster dose of MCC. CONCLUSION: A booster dose of MCC was safe and induced high seroprotection rate even 12-18 months after priming. MCC should be administered after maximum virologic suppression has been achieved. These results support the recommendation of 2-dose of MCC for primary immunization in HIV-infected children and adolescents with restored immune function.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Frota ACC, Ferreira B, Harrison LH, et al. Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil. Vaccine. 2017. PMID: 29100708. doi:10.1016/j.vaccine.2017.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。